Special Report: Creating a Safer Treatment to Counteract the Effect of Blood Thinners

January 14, 2011

LOS ANGELES, CA--(Marketwire - 01/14/11) - The search for viable alternatives to protamine is clearly an important one, but to date it has generated few successes. One prominent new player in the quest is PolyMedix, Inc. (OTC.BB:PYMX - News), based in Radnor, Pennsylvania. The company has developed novel small molecules, which it has dubbed "heptagonists," that act to reverse the anticoagulant properties of both heparin and its low molecular weight variant. They are designed to be administered whenever bleeding that results from the use of blood thinners is diagnosed.The company has shown that its heptagonist compounds, including the lead compound known as PMX-60056, exhibits a number of positive characteristics that may make it useful for this purpose.PolyMedix has completed four clinical studies with PMX-60056, including three studies that were designed to assess efficacy. Their efforts would not represent the first attempt of their kind. The most significant previous attempt to create a marketable anticoagulant reversal agent took place about two decades ago, when Biomarin developed a drug known as heparinase.A free, full report special report titled: "A Red-Blooded Medical Challenge: Creating a Safer Treatment to Counteract the Effect of Blood Thinners" appears at BiomedReports.com:http://biomedreports.com/2011011462418/a-red-blooded-medical-challenge-creating-a-safer-treatment-to-counteract-the-effect-of-blood-thinners.htmlBiotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can also access that information at:http://biomedreports.com/fda-calendar/fda-calendar.htmlNews developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReportsAbout BioMedReports.ComBioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content.